AGIO$30.5517.94%-6.68
After Hours: 31.40+0.85 +2.78%
Agios Pharmaceuticals Inc (AGIO)
Date: 2026-10-30 16:00O: 31.43H: 33.00L: 29.80C: 30.55Vol: 3.094M
Agios Pharmaceuticals Inc stock is traded at $30.55, with a volume of 3,094,260. It is down -17.94% in the last 24 hours and down -8.12% over the past month. Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236 and others.
Previous Close:
$37.23
Open:
$31.43
24h Volume:
3,094,260
Relative Volume:
2.34
Market Cap:
$1.82B
Revenue:
$66.05M
Net Income/Loss:
-$422.60M
P/E Ratio:
-
EPS:
-$7.25
Net Cash Flow:
-$384.73M
1W Performance:
-17.43%
1M Performance:
-8.12%
6M Performance:
+9.11%
1Y Performance:
-29.25%
1-Day Range:
$29.80$33.00
1-Week Range:
$29.80$38.69
52-Week Range:
$22.24$46.00
Agios Pharmaceuticals Inc Stock (AGIO) Company Profile
Name
Agios Pharmaceuticals IncSector
HealthcareIndustry
BiotechnologyPhone
617-649-8600Address
88 SIDNEY STREET, CAMBRIDGE, MA, USACompare AGIO vs VRTX, REGN, MRNA, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AGIO Agios Pharmaceuticals Inc | $30.55 | $1.82B | $66.05M | -$422.60M | -$384.73M | -$7.25 |
 VRTX Vertex Pharmaceuticals Inc | $558.88 | $141.65B | $12.34B | $4.34B | $3.71B | $16.87 |
 REGN Regeneron Pharmaceuticals Inc | $927.89 | $95.53B | $14.92B | $4.42B | $3.79B | $41.04 |
 MRNA Moderna Inc | $221.72 | $88.52B | $2.23B | -$3.19B | -$1.60B | -$8.15 |
 ARGX Argen X Se Adr | $892.87 | $56.15B | $4.16B | $1.29B | $734.26M | $19.58 |
 ONC Beone Medicines Ltd Adr | $370.33 | $41.89B | $5.76B | $514.49M | $1.10B | $4.48 |
Agios Pharmaceuticals Inc Stock (AGIO) Upgrades & Downgrades
Agios Pharmaceuticals Inc Stock (AGIO) Financials Data
Revenue
Net Income
Cash Flow
EPS
Agios Pharmaceuticals Inc Stock (AGIO) Insider Trading
- Gheuens SarahOct 26 '26Chief Medical Officer
- Transaction
- Sale
- Cost
- $37.69
- #Shares
- 7,866
- Value ($)
- 296,470
- #Shares Total
- 54,645
- SARAH GHEUENSOct 26 '26Officer
- Transaction
- Proposed Sale
- Cost
- $37.69
- #Shares
- 7,866
- Value ($)
- 296,468
- #Shares Total
- 0
- Gheuens SarahOct 22 '26Chief Medical Officer
- Transaction
- Option Exercise
- Cost
- $25.01
- #Shares
- 500
- Value ($)
- 12,505
- #Shares Total
- 55,145
- Gheuens SarahOct 22 '26Chief Medical Officer
- Transaction
- Sale
- Cost
- $37.52
- #Shares
- 500
- Value ($)
- 18,760
- #Shares Total
- 54,645
- SARAH GHEUENSOct 22 '26Officer
- Transaction
- Proposed Sale
- Cost
- $37.52
- #Shares
- 500
- Value ($)
- 18,760
- #Shares Total
- 0
- Gheuens SarahOct 21 '26Chief Medical Officer
- Transaction
- Option Exercise
- Cost
- $25.01
- #Shares
- 1,489
- Value ($)
- 37,240
- #Shares Total
- 56,134
- SARAH GHEUENSOct 21 '26Officer
- Transaction
- Proposed Sale
- Cost
- $37.53
- #Shares
- 1,489
- Value ($)
- 55,881
- #Shares Total
- 0
- Gheuens SarahOct 21 '26Chief Medical Officer
- Transaction
- Sale
- Cost
- $37.53
- #Shares
- 1,489
- Value ($)
- 55,882
- #Shares Total
- 54,645
- Gheuens SarahAug 04 '26Chief Medical Officer
- Transaction
- Sale
- Cost
- $30.48
- #Shares
- 30,000
- Value ($)
- 914,400
- #Shares Total
- 54,645
- SARAH GHEUENSAug 04 '26Officer
- Transaction
- Proposed Sale
- Cost
- $30.48
- #Shares
- 30,000
- Value ($)
- 914,283
- #Shares Total
- 0
